Windtree Announces Partnership With New Growth Advisors To Leverage Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction
Windtree Announces Partnership With New Growth Advisors To Leverage Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that it has engaged New Growth Advisors ("NGA"), a leading life sciences consulting firm chosen by companies seeking discreet, conflict-free, and knowledgeable advice on complex M&A, asset sale, research, capital markets, and licensing transactions, as its strategic advisor to lead a process in respect of Windtree's cardiovascular portfolio, including a potential out-licensing transaction or asset sale. NGA has advised on transactions with an aggregate value approaching $400 million from 2023 through 2024.
windtree therapeutics公司(「windtree」或「公司」)(納斯達克CM:WINT),一家專注於推進早期和晚期創新療法以治療關鍵病狀和疾病的生物技術公司,今天宣佈已委託新成長顧問(「NGA」),該公司是一家領先的生命科學諮詢公司,爲尋求在複雜的併購、資產出售、研究、資本市場和許可交易中尋求慎重、無衝突和知識淵博建議的公司選擇作爲其戰略顧問,以領導一個關於windtree心血管產品組合的過程,包括潛在的轉讓交易或資產出售。 NGA從2023年到2024年,已經就價值接近40000萬美元的交易提供建議。
The Company seeks to leverage the positive early cardiogenic shock and acute heart failure results (including the recent positive Phase 2b in early cardiogenic shock) to better address the breadth of opportunities and secure potentially non-dilutive funding via a partnership for istaroxime as well as the next generation, oral SERCA2a activators for all global territory ex-Greater China. NGA has been engaged to manage the current inbound interest as well as to run an expanded out-licensing process.
公司希望利用早期心原性休克和急性心力衰竭研究結果(包括近期早期心原性休克第20億期的積極結果),以更好地探索機會廣度,並通過夥伴關係獲得潛在的無稀釋資金,致力於將istaroxime及下一代口服SERCA2a激動劑在大中華以外的所有全球領土。NGA已受聘管理當前的入站利益,並運行一個擴大的轉讓流程。
The Company currently has a licensing agreement for the Greater China territory for istaroxime, dual mechanism SERCA2a activators and rostafuroxin with Lee's Pharmaceuticals (HK) Limited ("Lee's") for which it may receive up to $138 million in potential milestones and low double-digit royalties. Lee's pays for all development costs and is working with Windtree on the planning, Lee's expects to start Phase 3 in acute heart failure in its licensed territory in the first half of 2025.
公司目前與李氏製藥(香港)有限公司(「李氏」)就istaroxime、雙作用機制SERCA2a激動劑和rostafuroxin的大中華領土簽訂許可協議,公司可能獲得高達13800萬美元的潛在里程碑和低兩位數的專利費。李氏支付所有發展成本,並與windtree共同制定計劃,李氏預計將於2025年上半年在其許可領土內開始第3期急性心力衰竭研究。
譯文內容由第三人軟體翻譯。